Embecta Corp. (EMBC)

Market Cap	560.22M -22.5%
Revenue (ttm)	1.08B -2.5%
Net Income	139.50M +139.7%
EPS	2.36 +138.2%
Shares Out	59.22M
PE Ratio	4.01
Forward PE	3.39
Dividend	$0.60 (6.34%)
Ex-Dividend Date	Feb 27, 2026

Volume	693,284
Open	9.44
Previous Close	9.26
Day's Range	9.34 - 9.73
52-Week Range	8.47 - 15.55
Beta	1.10
Analysts	Buy
Price Target	18.50 (+95.56%)
Earnings Date	May 8, 2026

About EMBC

Embecta Corp., a medical device company, provides solutions to improve the health and wellbeing of people living with diabetes in the United States and internationally. The company’s products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient’s diabetes. It primarily sells its products to wholesalers and distributors. The company was formerly known as Berra Newco, Inc. Embecta Corp. was founded in 1924 and is headquartered in Parsippany, New Jersey.

• Industry: Medical Instruments & Supplies
• Sector: Healthcare
• Founded: 1924
• Employees: 1,850
• Stock Exchange: NASDAQ
• Ticker Symbol: EMBC
• Website: https://www.embecta.com

Financial Performance

In fiscal year 2025, Embecta's revenue was $1.08 billion, a decrease of -3.80% compared to the previous year's $1.12 billion. Earnings were $95.40 million, an increase of 21.84%.

Analyst Summary

According to 2 analysts, the average rating for EMBC stock is "Buy." The 12-month stock price target is $18.5, which is an increase of 95.56% from the latest price.

Price Target

$18.5

(95.56% upside)

Analyst Consensus: Buy